Literature DB >> 12484692

Lymphadenopathy and malignancy.

Andrew W Bazemore1, Douglas R Smucker.   

Abstract

The majority of patients presenting with peripheral lymphadenopathy have easily identifiable causes that are benign or self-limited. Among primary care patients presenting with lymphadenopathy, the prevalence of malignancy has been estimated to be as low as 1.1 percent. The critical challenge for the primary care physician is to identify which cases are secondary to malignancies or other serious conditions. Key risk factors for malignancy include older age, firm, fixed nodal character, duration of greater than two weeks, and supraclavicular location. Knowledge of these risk factors is critical to determining the management of unexplained lymphadenopathy. In addition, a complete exposure history, review of associated symptoms, and a thorough regional examination help determine whether lymphadenopathy is of benign or malignant origin. Unexplained lymphadenopathy without signs or symptoms of serious disease or malignancy can be observed for one month, after which specific testing or biopsy should be performed. While modern hematopathologic technologies have improved the diagnostic yields of fine-needle aspiration, excisional biopsy remains the initial diagnostic procedure of choice. The overall evaluation of lymphadenopathy, with a focus on findings suggestive of malignancy, as well as an approach to the patient with unexplained lymphadenopathy, will be reviewed.

Entities:  

Mesh:

Year:  2002        PMID: 12484692

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  27 in total

1.  Histological Surprises in Benign Cytologies after Lymph Node Biopsy-Surgeon's Knife Improving Patient Care.

Authors:  Mario Victor Newton; Rakesh S Ramesh; Suraj Manjunath; K ShivaKumar; Hemanth G Nanjappa; Ramu Damuluri; Elvis Peter Joseph; C Prasad
Journal:  Indian J Surg Oncol       Date:  2016-11-29

2.  The differential agglutination test as a diagnostic aid in cases of toxoplasmic lymphadenitis.

Authors:  Jose G Montoya; Andrew Berry; Fernando Rosso; Jack S Remington
Journal:  J Clin Microbiol       Date:  2007-02-21       Impact factor: 5.948

3.  Efficacy of colour Doppler ultrasound in diagnosis of cervical lymphadenopathy.

Authors:  Raghavendra Mahadev Naik; Anuradha Pai; Yadavalli Guruprasad; Rajesh Singh
Journal:  J Maxillofac Oral Surg       Date:  2012-08-24

4.  Clinico-pathological correlates of cervical lymphadenopathy: a hospital based study.

Authors:  Gautam Biswas; Anjan Das; Dibakar Haldar; Ankur Mukherjee; Sirshak Dutta; Ramanuj Sinha
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-06

Review 5.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

6.  Level 5 Lymphadenopathy Warrants Heightened Suspicion for Clinically Significant Pathology.

Authors:  M Cunnane; L Cheung; A Moore; S di Palma; A McCombe; L Pitkin
Journal:  Head Neck Pathol       Date:  2016-06-03

7.  Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience.

Authors:  Esra Akyüz Özkan; Ceren Canbey Göret; Zeynep Tuba Özdemir; Serdar Yanık; Nuri Emrah Göret; Meryem Doğan; Fatma Gökşin Cihan; Ayşe Neslin Akkoca
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  Metastatic Carcinoma with Associated Lymphoadenopathy and Acquired Horner's Syndrome Portrayed in a Third Century CE Roman Bust.

Authors:  Raffaella Bianucci; Casey L Kirkpatrick; Francesco Maria Galassi; Antonio Perciaccante; Simon T Donell; Otto Appenzeller; Andreas G Nerlich
Journal:  Head Neck Pathol       Date:  2020-11-23

9.  Splenomegaly, hypersplenism and peripheral blood cytopaenias in patients with classical Anderson-Fabry disease.

Authors:  João Paulo Oliveira; Carmen Valbuena; António Baldaia Moreira; Elsa Fonseca; Carlos Soares; Elisa Leão Teles; Stephen Waldek
Journal:  Virchows Arch       Date:  2008-09-02       Impact factor: 4.535

Review 10.  Cell-blocks and hematolymphoid lesions.

Authors:  Ahmed Alrajjal; Moumita Choudhury; Jay Yang; Ali Gabali
Journal:  Cytojournal       Date:  2021-03-31       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.